source
- Tempus AI to buy cancer test maker Personalis for $1.5 billionTempus AI announced it will acquire Personalis, a California-based company that offers a molecular residual disease test for cancer, in a transaction valued at $1.5 billion. The deal, priced at $1…
- Baxter alerts users to potential air bubble risk in Duo-Vent IV solution setsThe FDA’s Center for Devices and Radiological Health has issued an early alert about a possible high-risk issue with Baxter’s Duo-Vent intravenous solution sets. The devices may contain air bubbles…